Maria Nicoletti
About
In The Last Decade
Maria Nicoletti
22 papers receiving 879 citations
Peers
Comparison fields: 5 of 75
- Molecular Biology 458
- Oncology 383
- Cancer Research 346
- Cell Biology 145
- Hematology 91
Countries citing papers authored by Maria Nicoletti
This map shows the geographic impact of Maria Nicoletti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Nicoletti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Nicoletti more than expected).
Fields of papers citing papers by Maria Nicoletti
This network shows the impact of papers produced by Maria Nicoletti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Nicoletti. The network helps show where Maria Nicoletti may publish in the future.
Co-authorship network of co-authors of Maria Nicoletti
This figure shows the co-authorship network connecting the top 25 collaborators of Maria Nicoletti. A scholar is included among the top collaborators of Maria Nicoletti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Nicoletti. Maria Nicoletti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Cancer of the uterine cervix is susceptible to anti-EGF-R antibody EMD 55,900 therapy. | 4 |
| 2 | Pituitary tumor-transforming gene (PTTG): a novel target for anti-tumor therapy. | 27 |
| 3 | 62 | |
| 4 | 3 | |
| 5 | 104 | |
| 6 | The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. | 52 |
| 7 | 12 | |
| 8 | Small molecules in anti-angiogenic therapy. | 4 |
| 9 | Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. | 49 |
| 10 | 4 | |
| 11 | Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. | 71 |
| 12 | Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. | 74 |
| 13 | 14 | |
| 14 | Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. | 111 |
| 15 | Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. | 57 |
| 16 | 1 | |
| 17 | 22 | |
| 18 | 29 | |
| 19 | 22 | |
| 20 | 105 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.